At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02359 WUXI APPTEC
Trading 01-23 13:24:46
113.600
+0.400
+0.35%
High115.200
Low113.200
Vol2.16M
Open114.100
D1 Closing113.200
Amplitude1.77%
Mkt Cap338.98B
Tradable Cap57.99B
Total Shares2.98B
T/O246.07M
T/O Rate0.42%
Tradable Shares510.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
JPMorgan Reduces Stake in WUXI APPTEC (02359) by Approximately 2.52 Million Shares at HK$119.32 Per Share
Global 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects
Hong Kong Stocks Movement | CRO Concept Stocks Lead Gains with WUXI APPTEC (02359) Forecasting Doubled Net Profit; Sector Poised for "Davis Double Play"
Hong Kong Stock Announcement Highlights | WuXi AppTec Forecasts 2025 Net Profit Attributable to Shareholders of Approximately RMB 19.151 Billion, Up ~102.65% YoY
WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.